Min Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Min Yi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Brian I. Rini
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
33 shared publications - Elaine T. Lam
University of Colorado Anschutz Medical Campus 5 Department of Medical Oncology Aurora, CO 80045
33 shared publications - Erick Gamelin
20Acrivon Therapeutics, Watertown, Massachusetts
33 shared publications - Gregory Obara
Comprehensive Cancer Centers of Nevada, Henderson, Nevada
33 shared publications - James Brugarolas
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
33 shared publications - James Hamilton
Arrowhead Pharmaceuticals, Pasadena, California
33 shared publications
Latest Publications
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S3: Comparison of ARO-HIF2 Plasma Exposures Following the First and the Third Weekly Dose
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S3: Comparison of ARO-HIF2 Plasma Exposures Following the First and the Third Weekly Dose
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S4: Tumor Tissue Distribution of ARO-HIF2 Trigger
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S4: Tumor Tissue Distribution of ARO-HIF2 Trigger
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S7. Summary of Percent Change in Vascular Endothelial Growth Factor (pg/mL) by Visit
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S7. Summary of Percent Change in Vascular Endothelial Growth Factor (pg/mL) by Visit
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S1: Summary of Treatment Emergent Adverse Events of Special Interest Related to ARO-HIF2 (Safety Analysis Set)
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S1: Summary of Treatment Emergent Adverse Events of Special Interest Related to ARO-HIF2 (Safety Analysis Set)
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S6: Summary of Hemoglobin (g/dL) by Visit
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S6: Summary of Hemoglobin (g/dL) by Visit
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S3: ARO-HIF2 Plasma Concentration-Time Profiles by Treatment and Dosing Week
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S3: ARO-HIF2 Plasma Concentration-Time Profiles by Treatment and Dosing Week
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S3: Comparison of ARO-HIF2 Plasma Exposures Following the First and the Third Weekly Dose
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S3: Comparison of ARO-HIF2 Plasma Exposures Following the First and the Third Weekly Dose
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S4: Tumor Tissue Distribution of ARO-HIF2 Trigger
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S4: Tumor Tissue Distribution of ARO-HIF2 Trigger
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S2: Summary of ARO-HIF2 Plasma Pharmacokinetic Parameters
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Table S2: Summary of ARO-HIF2 Plasma Pharmacokinetic Parameters
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S1. AROHIF21001 Study Design
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Figure S1. AROHIF21001 Study Design